BioSpace News Archive

Bayer announced today that it received approval from the United States (U.S.) Food and Drug Administration (FDA) for an update to the label for KERENDIA® (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA), to include findings from the FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).

Matregenix announces a grant award from the National Institute of Dental & Craniofacial Research under the auspices of the Small Business Innovation Research program and National Institutes of Health.

Cambrex announced the completion of the first phase of its $30 million investment in its small molecule active pharmaceutical ingredient manufacturing facility in High Point, North Carolina.

Medtronic plc, a global leader in healthcare technology, announced results from the Medtronic ADAPT study were published in The Lancet Diabetes & Endocrinology.

Vaxart, Inc. reported positive top-line data from the first part of a planned two-part Phase II study of its Wuhan S-only oral pill COVID-19 vaccine candidate, VXA-CoV2-1.1-S.

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced participation in the following investor conferences in September.

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that senior management will present at the following upcoming investor conferences.

Ibex Medical Analytics, the leader in AI-powered cancer diagnostics, announced outstanding outcomes for the Galen™ Breast solution in diagnosing multiple cancer types and further expansion of its AI portfolio for breast cancer diagnosis.

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Aetna has updated their spinal cord stimulation (SCS) coverage policy to explicitly cover painful diabetic neuropathy (PDN), effective August 29, 2022.

IMV Inc., a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced that members of IMV’s executive management team will be presenting at two investor conferences in September.